CSL Ltd (ASX: CSL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

CSL Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $134.81 billion
P/E Ratio 42.74
Dividend Yield 0.99%
Shares Outstanding 455.67 million
Earnings per share 5.210
Dividend per share 2.94
Year To Date Return 5.52%
Earnings Yield 2.34%
Franking 10.0018871485%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

CSL Ltd (ASX: CSL)
Latest News

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
02 Sep 2021 $1.5897 10.00% Final 30 Sep 2021
04 Mar 2021 $1.3491 0.00% Interim 01 Apr 2021
10 Sep 2020 $1.4696 0.00% Final 09 Oct 2020
11 Mar 2020 $1.4713 0.00% Interim 09 Apr 2020
10 Sep 2019 $1.4545 0.00% Final 11 Oct 2019
13 Mar 2019 $1.2032 0.00% Interim 12 Apr 2019
11 Sep 2018 $1.2782 0.00% Final 12 Oct 2018
14 Mar 2018 $1.0050 0.00% Interim 13 Apr 2018
12 Sep 2017 $0.9153 0.00% Final 13 Oct 2017
15 Mar 2017 $0.8378 0.00% Interim 13 Apr 2017
13 Sep 2016 $0.8867 0.00% Final 07 Oct 2016
23 Mar 2016 $0.8147 0.00% Interim 15 Apr 2016
07 Sep 2015 $0.8999 0.00% Final 02 Oct 2015
16 Mar 2015 $0.7439 0.00% Interim 10 Apr 2015
08 Sep 2014 $0.6485 0.00% Final 03 Oct 2014
05 Mar 2014 $0.5888 0.00% Interim 04 Apr 2014
09 Sep 2013 $0.5698 0.00% Final 04 Oct 2013
05 Mar 2013 $0.4866 0.00% Interim 05 Apr 2013
17 Sep 2012 $0.4700 0.00% Final 12 Oct 2012
14 Mar 2012 $0.3600 0.00% Interim 13 Apr 2012
19 Sep 2011 $0.4500 4.44% Final 14 Oct 2011
08 Mar 2011 $0.3500 0.00% Interim 08 Apr 2011
13 Sep 2010 $0.4500 11.73% Final 08 Oct 2010
09 Mar 2010 $0.3500 0.00% Interim 09 Apr 2010
14 Sep 2009 $0.4000 0.00% Final 09 Oct 2009
17 Sep 2007 $0.5500 50.00% Final 12 Oct 2007
30 Aug 2005 $0.1000 17.80% Special 10 Oct 2005

CSL ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About CSL Ltd

CSL Limited (ASX: CSL) is an Australian-based global biotechnology company that develops and delivers innovative biotherapies and vaccines to protect public health and help people with life-threatening medical conditions live full lives.

CSL has been in operation for more than a century and was listed on the ASX in 1994. Today, the blue-chip healthcare company sits as one of the largest on the ASX. CSL’s operational businesses include CSL Behring and Seqirus, and the company operates predominantly in Australia, the United States, Germany, the United Kingdom and Switzerland.

More recently, COVID-19 has produced headwinds for the biotherapeutics giant with plasma collections impacted by pandemic restrictions. The company’s growth in treatment sales has also been tempered by a reduction in doctor visits.

CSL Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
22 Oct 2021 $295.86 $1.21 0.41% 1,071,329 $295.97 $297.96 $294.80
21 Oct 2021 $294.65 $-3.02 -1.01% 882,794 $298.80 $298.80 $294.65
20 Oct 2021 $297.67 $1.49 0.50% 543,452 $299.90 $299.90 $297.07
19 Oct 2021 $296.18 $1.88 0.64% 570,211 $293.45 $296.54 $293.11
18 Oct 2021 $294.30 $-3.26 -1.10% 737,583 $297.00 $298.00 $292.63
15 Oct 2021 $297.56 $0.66 0.22% 496,719 $299.90 $301.14 $296.20
14 Oct 2021 $296.90 $2.85 0.97% 569,698 $298.90 $299.84 $296.43
13 Oct 2021 $294.05 $1.37 0.47% 535,631 $291.32 $295.25 $290.69
12 Oct 2021 $292.68 $5.18 1.80% 1,001,450 $289.83 $293.99 $288.51
11 Oct 2021 $287.50 $-2.96 -1.02% 496,957 $288.00 $290.24 $285.16
08 Oct 2021 $290.46 $2.40 0.83% 528,454 $293.20 $293.20 $287.13
07 Oct 2021 $288.06 $1.87 0.65% 541,791 $286.61 $289.00 $286.47
06 Oct 2021 $286.19 $-0.48 -0.17% 731,118 $293.00 $294.47 $285.51
05 Oct 2021 $286.67 $-0.66 -0.23% 499,359 $286.99 $288.74 $285.12
04 Oct 2021 $287.33 $-1.54 -0.53% 353,019 $291.83 $292.24 $286.08
01 Oct 2021 $288.87 $-4.53 -1.54% 773,622 $293.13 $293.79 $287.12
30 Sep 2021 $293.40 $6.54 2.28% 984,927 $288.41 $293.40 $287.03
29 Sep 2021 $286.86 $-7.61 -2.58% 976,701 $291.32 $291.39 $285.33
28 Sep 2021 $294.47 $-11.79 -3.85% 748,994 $301.26 $301.46 $294.47
27 Sep 2021 $306.26 $-5.75 -1.84% 625,526 $310.00 $310.76 $305.51

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
13 Oct 2021 Paul Perreault Issued 31 $9,303,742
Issue of securities. 87,719 Performance Share Units
04 Oct 2021 Robert Cuthbertson Issued 179 $54,661
Issue of securities. 4,659 - Performance Share Units & Rights
VWAP
04 Oct 2021 Robert Cuthbertson Expiry 2 $586,440
As advised by the company. 4,480 - Performance Share Units
Lapsing of unvested Performance Share Units
01 Sep 2021 Paul Perreault Sell 15 $4,841,916
On-market trade.
01 Sep 2021 Paul Perreault Exercise 34 $10,680,259
Conversion of securities. 63,164 - Performance Share Units
01 Sep 2021 Paul Perreault Buy 34 $10,680,259
Conversion of securities. As per announcement on 03/09/2021
01 Sep 2021 Paul Perreault Expiry 7 $2,189,831
As advised by the company. 56,079 - Performance Share Units
7,085 Performance Share Units as a result of the lapse of Performance Share Units
26 Aug 2021 Bruce Brook Issued 240 $73,288
Issue of securities. 240 - Rights
Volume Weighted Average Price
26 Aug 2021 Duncan Maskell Issued 417 $127,339
Issue of securities. 417 - Rights
Volume Weighted Average Price
26 Aug 2021 Marie McDonald Issued 240 $73,288
Issue of securities. 240 - Rights
Volume Weighted Average Price
26 Aug 2021 Brian McNamee Issued 569 $173,755
Issue of securities. 569 - Rights
Volume Weighted Average Price
26 Aug 2021 Carolyn Hewson Issued 401 $122,453
Issue of securities. 401 - Rights
Volume Weighted Average Price
26 Aug 2021 Alison Watkins Issued 243 $74,204
Issue of securities. 243 - Rights
Volume Weighted Average Price
26 Aug 2021 Megan Clark Issued 160 $48,859
Issue of securities. 160 - Rights
Volume Weighted Average Price
23 Aug 2021 Megan Clark Exercise 80 $23,604
Conversion of securities.
23 Aug 2021 Megan Clark Buy 80 $23,604
Conversion of securities.
23 Aug 2021 Carolyn Hewson Buy 202 $59,600
Conversion of securities.
23 Aug 2021 Carolyn Hewson Exercise 202 $59,600
Conversion of securities.
23 Aug 2021 Brian McNamee Exercise 278 $82,023
Conversion of securities.
23 Aug 2021 Brian McNamee Buy 278 $82,023
Conversion of securities.
23 Aug 2021 Marie McDonald Buy 121 $35,701
Conversion of securities.
23 Aug 2021 Marie McDonald Exercise 121 $35,701
Conversion of securities.
23 Aug 2021 Bruce Brook Exercise 80 $23,604
Conversion of securities.
23 Aug 2021 Bruce Brook Buy 80 $23,604
Conversion of securities.
20 Aug 2021 Megan Clark Buy 160 $48,889
On-market trade.
23 Feb 2021 Megan Clark Exercise 81 $23,899
Conversion of securities. 80 - Rights
23 Feb 2021 Megan Clark Buy 81 $23,899
Conversion of securities.
23 Feb 2021 Marie McDonald Exercise 121 $35,701
Conversion of securities. 121 - Rights
23 Feb 2021 Marie McDonald Buy 121 $35,701
Conversion of securities.
23 Feb 2021 Bruce Brook Exercise 81 $23,899
Conversion of securities. 80 - Rights
23 Feb 2021 Bruce Brook Buy 81 $23,899
Conversion of securities.
23 Feb 2021 Brian McNamee Buy 278 $82,023
Conversion of securities.
23 Feb 2021 Brian McNamee Exercise 278 $82,023
Conversion of securities. 278 - Rights
23 Feb 2021 Carolyn Hewson Transfer 174 $46,625
Off-market transfer. Assuming 174 Direct shares transferred to Indirect shares.
23 Feb 2021 Carolyn Hewson Transfer 174 $46,625
Off-market transfer. Assuming 174 Direct shares transferred to Indirect shares.
23 Feb 2021 Carolyn Hewson Buy 202 $59,600
Conversion of securities.
23 Feb 2021 Carolyn Hewson Exercise 202 $59,600
Conversion of securities. 202 - Rights

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Ms Carolyn Judith Hewson Non-Executive Director Dec 2019
Ms Hewson is a former investment banker with over 35 years of experience in the finance sector. She was previously an executive director of Schroders Australia Limited and has extensive financial markets, risk management and investment management expertise. She has long-term Non-Executive experience in a number of sectors bringing a breadth of experience and insight on strategy, capital management and portfolio optimisation through cycles, financial and non-financial risk, social value, organisational culture and the changing external environment. In 2009, Ms Hewson was made an Officer in the Order of Australia for her services to the broader community and to business. Currently, she is Director of Reserve Bank of Australia (since April 2021) Director of Infrastructure SA (since January 2019); Former Director of BHP Group Limited and BHP Group Plc (from March 2010 to November 2019),Stockland Group (from March 2009 to September 2018) Former Trustee Westpac Foundation (from May 2015 to May 2019) and Former Member of Federal Government Growth Centres Advisory Committee (from January 2015 to May 2021). She is Chair of the Corporate Governance Committee, member of the Risk Management Committee and Human Resources Committee.
Ms Alison Mary Watkins Non-Executive Director Aug 2021
Ms Watkins has experience of manufacturing, agriculture, consumer goods, retail and financial services. Ms Watkins was most recently the group managing director of ASX-listed Coca-Cola Amatil Limited, where she was responsible for operations in Australia, New Zealand, Indonesia and across the South Pacific region. Ms Watkins holds a Bachelor of Commerce from the University of Tasmania, is a fellow of the Institute of Chartered Accountants, the Financial Services Institute of Australasia, and the Australian Institute of Company Directors. Currently, she is Director of Reserve Bank of Australia (since Dec 2020); Director Wesfarmers Limited (effective from 1 September 2021); Chancellor, University of Tasmania (effective from 1 July 2021); Director of Centre for Independent Studies (since December 2011); Director of Business Council of Australia (since August 2015); and Former Group Managing Director of Coca-Cola Amatil Limited (from March 2014 to May 2021). She is Member of the Risk Management and Human Resources Committee.
Dr Brian Anthony McNamee Non-Executive DirectorNon-Executive Chairman Jan 1990
Dr McNamee has experience in the biopharmaceutical industry, with a focus on strategy and creating long-term shareholder value. Dr McNamee was the Chief Executive Officer and Managing Director of CSL from 1990 until 2013. Since leaving his executive role at CSL, Dr McNamee has served as a senior advisor to private equity group Kohlberg Kravis Roberts. He has also pursued a number of private equity and interests in small cap healthcare companies, and in 2014 served on the panel of the Australian Government's Financial System Inquiry. In 2009, he was made an Officer of the Order of Australia for service to business and commerce. Currently, he is Chair of Geoff Ogilvy Foundation (since May 2021) and Chair of Genesis Care Limited (since July 2019). He is Member of the Innovation, Development Committee, Corporate Governance and Market Disclosure Committee.
Dr Robert Andrew Cuthbertson Non-Executive Director Oct 2018
Mr Cuthbertson has over 35 years of experience in medical research and biotech development with large biopharmaceutical companies and medical organizations. He also has Non-Executive director experience. Prior to CSL, he was a senior scientist at Genentech Inc, a biotechnology company dedicated to pursuing ground-breaking science to discover and develop medicine for people with life-threatening diseases. Professor Cuthbertson spent five years doing molecular biology research as a staff member at the Howard Florey Institute in Melbourne, Australia and the National Institutes of Health in Maryland, US. In 2016, he was made an Officer of the Order of Australia and appointed Enterprise Professor at the University of Melbourne. Currently, he is Director of the Centre of Eye Research Australia (since March 2017),Grattan Institute (since January 2019) and Member of the Council of the University of Melbourne (since January 2020). He is Chair of the Innovation and Development Committee.
Mr Bruce Robert Brook Non-Executive Director Aug 2011
Mr Brook has experience in diverse industries, including mining, finance, manufacturing and chemicals. In particular, Mr Brook has insight and experience in relation to risk, capital discipline, change management, corporate culture and creating shareholder value. Mr Brook was chief financial officer of WMC Resources Limited from 2002 to 2005. He also held key executive roles including deputy chief finance officer of ANZ Banking Group Limited, group chief accountant of Pacific Dunlop Limited and general manager, Group Accounting positions at CRA Limited and Pasminco Limited. Currently he is Director of Djerriwarrh Investments Limited, Guide Dogs Victoria,Incitec Pivot Limited, and Former Director of the Deep Exploration Technologies Co-operative Research Center Limited. He is Chair of risk committee and member of corporate governance committee.
Professor Duncan John Maskell Non-Executive Director Aug 2021
Prof Maskell has international experience in science and commerce, developed across a 30-year career in research, academia and entrepreneurship. Prof Maskell is the Vice-Chancellor of the University of Melbourne. Prior to this he was Senior Pro-Vice-Chancellor at the University of Cambridge in the United Kingdom, where he was responsible for planning and resources for the institution's operations. As research specialist in infectious diseases, Professor Maskell has also held roles at the University of Oxford, Imperial College London and Wellcome Biotech. Prof Maskell has had experience across the private sector, involved in the commercialisation of research initiatives. He has co-founded several biotech companies, including Arrow Therapeutics, which was sold to biopharmaceutical company AstraZeneca, and Discuva, which was sold to Summit Therapeutics. He has also served as a Non-executive Director of Genus Plc, a FTSE 250 company.
Mr Paul Perreault Executive DirectorChief Executive OfficerManaging Director Feb 2013
Mr Perreault has more than 35 years of experience across both the global biotech and pharmaceutical industries. He was appointed Chief Executive Officer and Managing Director of CSL Limited in July 2013, and was appointed to the CSL Board of Directors the same year. Mr Perreault, who previously served as CSL Behring's president, joined CSL in 2004 with the acquisition of Aventis Behring. Prior to CSL, he spent more than 15 years in key senior roles at Wyeth-Ayerst Laboratories, now part of Pfizer. Currently, he is Director of the US Pharmaceutical Research and Manufacturers of America Association (PhRMA) (since December 2020). He is Member of the Innovation and Development Committee and Securities and Market Disclosure Committee.
Ms Marie Elizabeth McDonald Non-Executive Director Aug 2013
Ms McDonald has executive and Non-Executive experience in a number of sectors including law, medical research, manufacturing and chemicals. Through these roles, Ms McDonald brings experience and insight on financial markets, risk and compliance and change management. Ms McDonald is a former lawyer with over 30 years of experience in the legal sector. She was previously a partner of Ashurst, specialising in mergers and acquisitions and corporate governance. She held the role of National Head of Mergers and Acquisitions and was Chair of the Corporations Committee of the Business Law Section of the Law Council of Australia and a member of the Australian Takeovers Panel for nine years. Currently, she is Director of Nanosonics Limited (since October 2016); Director of Nufarm Limited (since March 2017); Director of the Walter & Eliza Hall Institute of Medical Research (since October 2016). She is member of risk committee and human resources committee.
Dr Megan Elizabeth Clark Non-Executive Director Feb 2016
Dr Clark has executive and Non-Executive experience across a range of sectors, including scientific research, health, investment banking and financial services, education and mining. Through her roles, Dr Clark brings strategic perspective and global experience, with a focus on risk and proven health, safety and environment and technology performance. In 2014 Dr Clark was made a Companion of the Order of Australia for eminent service to scientific research and development. Dr Clark was chief executive of the Commonwealth Scientific and Industrial Research Organisation (CSIRO) from 2009 until November 2014. Prior to joining CSIRO, she was a director at NM Rothschild and Sons (Australia) and held senior positions at BHP, including vice president (Technology) and vice president (Health, Safety and Environment). Currently she is Director of Rio Tinto Limited and Rio Tinto Plc (since November 2014) Member of the Australian Advisory Board of the Bank of America, (since July 2010); Member of the Global Advisory Council of the Bank of America Corporation (since December 2019); Deputy Chancellor of Monash University (since January 2021); Chair of the Australian Space Agency Advisory Board (since January 2021); Former Director of Care Australia Limited (from May 2015 to June 2020); and Head of the Australian Space Agency (from June 2018 to December 2020). She is Chair of the Human Resources Committee; Member of the Corporate Governance and Innovation and Development Committee.
Ms Fiona Mead Company SecretaryHead of Group Governance Jun 2018
-
Joy Linton Chief Financial Officer
-
Paul McKenzie Chief Operating Officer
-
Fiona Mead Company SecretaryHead of Group Governance
-
Bill Campbell Executive Vice President Chief Commercial Officer
-
Mark Hill Executive Vice President Chief Digital Information Officer
-
Elizabeth Walker Executive Vice President Chief Human Resources Officer
-
Greg Boss Executive Vice President Legal and CSL Group General Counsel
-
Alan Wills Executive Vice President Strategy and Business Development
-
Bill Mezzanotte Head Research & Development and Chief Medical Officer
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 149,095,937 32.76%
P Morgan Nominees Australia Pty Limited 76,711,952 16.86%
Citicorp Nominees Pty Limited 38,103,520 8.37%
National Nominees Limited 13,380,917 2.94%
BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C> 8,178,416 1.80%
BNP Paribas Noms Pty Ltd <Drp> 5,884,043 1.29%
Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 4,446,931 0.98%
BNP Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C> 3,234,496 0.71%
HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> 3,074,732 0.68%
Australian Foundation Investment Company Limited 2,053,312 0.45%
Netwealth Investments Limited <Wrap Services A/C> 1,834,241 0.40%
Custodial Services Limited <Beneficiaries Holding A/C> 1,555,184 0.34%
Solium Nominees (Australia) Pty Ltd <Allocated A/C> 1,420,857 0.31%
Argo Investments Limited 1,113,370 0.24%
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> 1,058,967 0.23%
D W S Nominees Pty Ltd 793,090 0.17%
National Nominees Limited <N A/C> 666,219 0.15%
Mutual Trust Pty Ltd 650,424 0.14%
AMP Life Limited 629,191 0.14%
Milton Corporation Limited 601,198 0.13%

Frequently Asked Questions

CSL originally floated in 1994 at $2.30 per share. However, taking into account share buybacks the company has embarked on, the adjusted entry price is equivalent to around 76 cents. Given CSL’s current share price, original shareholders would be very pleased!

CSL has paid twice yearly dividends every year since late 1997, a little over three years after the company’s initial listing on the ASX. Up until early 2005, CSL’s dividends were all fully franked. Since then, franking credits have been intermittent.

In 2021, CSL paid an interim unfranked dividend of $1.34 on 1 April and a final dividend of $1.58 (10% franked)  on 30 September.

CSL has a dividend reinvestment plan however it has not been active since 2004. Instead, CSL periodically executes share buybacks as a way of delivering additional returns for shareholders.

Profile

since

Note